Every issue of our magazine consists of over 100 pages of the latest newsand articles from the pharmaceutical sector. We aim at providing a quality and engaging editorial for our prestigious audience. Contributions for our magazine are sought from professional experts of the sector. We are willing to include you in our editorial mix. The interactive links throughout the magazine lead to additional supporting information to giveour readership a highly informative experience and relevant information at their fingertips.
The relationship between pharmaceutical and biopharmaceutical companies and drug delivery system manufacturers has evolved over the past 20 years. In the past, the relationships were purely transactional, but this has changed over the last two decades.
Significant innovation in disease treatment, including the increased focus on complex biologic therapies1, has resulted in important industry trends that have had an impact on many aspects of aseptic processing.
While the requirements for serialization in the pharmaceutical supply chain are generally regarded as inevitable counterfeiting is simply too large of a problem to not be addressed there is some uncertainty around the specifics,particularly globally.
Digital technology has been driving change throughout the life science industry for years, however the sector is currently standing on the precipice of revolutionary development – some organizations have already taken the jump towards a more digital future.
The Falsified Medicines Directive 2011/62/EU, which is due for adoption in February 2019, will require pharmaceuticalcompanies to apply serialisation codes to every applicable pack (OTC and some minor exemptions).